Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Osiris Therapeutics Inc updates on acquisition of Osiris' culture-expanded mesenchymal stem cell business


Wednesday, 9 Apr 2014 08:00am EDT 

Osiris Therapeutics Inc:On Oct. 2013 signed agreement with subsidiary of Mesoblast Ltd.For acquisition of Osiris' culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal.Transaction worth upto $100 mln in initial consideration and milestone payments as well as future royalties.On April 8, receipt of $15 mln cash payment for Prochymal. 

Company Quote

13.15
-0.14 -1.05%
18 Sep 2014